WRBY Warby Parker (WRBY) Insider Trading, Ownership & Congress Trades
Medical Devices · Ophthalmic goods · CIK 0001504776
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
195
13F, latest reported quarter
Conversions, 180 days
15
Codes C/M, not in net · $0 priced
What the filings say about WRBY
Insiders, 180 days
-$23.5M net sold
6 sellers · 14% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$3.2M
2 notices
Warby Parker insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Warby Parker Inc. insiders sold a net $23.5M of stock across 454 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-27.
Insider
Filed
Shares
Value
Since filing
Context
- 61 earlier Form 4 trades (code P or S) here by this insider (61 sales), the last on Jul 6, 2026.
- The trade is 277.6% of the 36,020 shares held after it.
- 1 other insider sold within 30 days.
- 195 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Executive Officer Blumenthal Neil Harris sold about $2.8M of WRBY under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 195 funds added in the latest 13F quarter.Context
- 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jul 1, 2026.
- The trade is 3.6% of the 420,201 shares held after it.
- 1 other insider sold within 30 days.
- 195 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Raider Jeffrey Jacob sold about $415.5K of WRBY under a 10b5-1 plan on Oct 1, 2026; 1 other insider sold within 30 days and 195 funds added in the latest 13F quarter.Context
- 60 earlier Form 4 trades (code P or S) here by this insider (60 sales), the last on Jul 1, 2026.
- The trade is 29.6% of the 31,112 shares held after it.
- 4 other insiders sold within 30 days.
- 195 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Executive Officer Blumenthal Neil Harris sold about $275.9K of WRBY on Jul 6, 2026; 4 other insiders sold within 30 days and 195 funds added in the latest 13F quarter.Context
- 52 earlier Form 4 trades (code P or S) here by this insider (52 sales), the last on Jul 1, 2026.
- The trade is 174.7% of the 31,112 shares held after it.
- 4 other insiders sold within 30 days.
- 195 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Executive Officer Gilboa David Abraham sold about $1.6M of WRBY on Jul 6, 2026; 4 other insiders sold within 30 days and 195 funds added in the latest 13F quarter.Context
- 59 earlier Form 4 trades (code P or S) here by this insider (59 sales), the last on Jun 29, 2026.
- The trade is 699.6% of the 31,112 shares held after it.
- 4 other insiders sold within 30 days.
- 195 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Co-Chief Executive Officer Blumenthal Neil Harris sold about $6.4M of WRBY on Jul 1, 2026, the largest insider sale at the company since 2025; 4 other insiders sold within 30 days and 195 funds added in the latest 13F quarter.454 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$23.5M over 180 days
-$3.2M over 90 days
below 94% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
195 funds bought in last quarter
more than 82% of Medical Devices
Revenue
+13.0% year over year
more than 56% of Medical Devices
Margin
0.2% net margin
more than 68% of Medical Devices
Buybacks
no share repurchases reported
Short interest
19.2% of the float short (float per yahoo 2026-10-26) · 4.4 days to cover · settled 2026-09-30
more than 97% of Medical Devices
What changed in the last 30 days
Oct 2Co-Chief Executive Officer Blumenthal Neil Harris sold $2.8M under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 2Director Raider Jeffrey Jacob sold $415.5K under a 10b5-1 plan (Oct 1)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 1Director NEIL BLUMENTHAL filed to sell $2.8M by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 1Director JEFFREY RAIDER filed to sell $416.7K by Oct 1 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch WRBY
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+15.8%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns WRBY: institutional holders (13F)
13F holdings, latest reported quarter
15,577,440 sh
$472.6M
15,309,616 sh
$464.5M
11,110,949 sh
$334.7M
6,396,513 sh
$194.1M
5,983,328 sh
$181.5M
Congress trades in WRBY
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
WRBY planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
NEIL BLUMENTHAL
Filed 2026-10-01
$2.8M
JEFFREY RAIDER
Filed 2026-10-01
$416.7K
NEIL BLUMENTHAL
Filed 2026-07-06
$269.2K
DAVID GILBOA
Filed 2026-07-06
$1.6M
NEIL BLUMENTHAL
Filed 2026-07-01
$6.6M
WRBY mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Simplify Health Care ETF
$19.6M position · as of 2026-06-30
5.5%
Motley Fool Small-Cap Growth ETF
$1.5M position · as of 2026-05-31
2.5%
Ranger Micro Cap Fund
$262.0K position · as of 2026-07-31
2.2%
Ranger Small Cap Fund
$273.3K position · as of 2026-07-31
2.2%
Transamerica Small Cap Growth
$1.8M position · as of 2026-07-31
2.2%
Vaughan Nelson Small Cap Fund
$30.0M position · as of 2026-06-30
2.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $23.5M sold by insiders over 180 days, 195 funds added last quarter, $3.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
WRBY financials
Revenue growth
+13.0%
XBRL, annual
Net margin
0.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$911.6M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM WRBY
| FY Dec 2025 | $871.9M |
| FY Dec 2024 | $771.3M |
| FY Dec 2023 | $669.8M |
| FY Dec 2022 | $598.1M |
| FY Dec 2021 | $540.8M |
| Jun 2026 | $235.5M |
| Mar 2026 | $242.4M |
| Dec 2025 | $212.0M |
| Sep 2025 | $221.7M |
| Jun 2025 | $214.5M |
| Mar 2025 | $223.8M |
| Dec 2024 | $190.6M |
| Sep 2024 | $192.4M |
At each fiscal year end
Single quarter
Net margin, TTM
+0.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM WRBY
| FY Dec 2025 | +0.2% |
| FY Dec 2024 | -2.6% |
| FY Dec 2023 | -9.4% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -26.7% |
| Jun 2026 | +2.0% |
| Mar 2026 | +1.3% |
| Dec 2025 | -2.8% |
| Sep 2025 | +2.6% |
| Jun 2025 | -0.8% |
| Mar 2025 | +1.6% |
| Dec 2024 | -3.6% |
| Sep 2024 | -2.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$21.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM WRBY
| FY Dec 2025 | $43.7M |
| FY Dec 2024 | $34.7M |
| FY Dec 2023 | $7.3M |
| FY Dec 2022 | -$49.8M |
| FY Dec 2021 | -$80.5M |
| Jun 2026 | $6.8M |
| Mar 2026 | $8.4M |
| Dec 2025 | $8.1M |
| Sep 2025 | -$1.5M |
| Jun 2025 | $23.9M |
| Mar 2025 | $13.2M |
| Dec 2024 | $2.2M |
| Sep 2024 | $13.1M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity WRBY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt WRBY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+2.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity WRBY
| FY Dec 2025 | +0.5% |
| FY Dec 2024 | -6.4% |
| FY Dec 2023 | -21.5% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -328.3% |
| Jun 2026 | +2.1% |
| Mar 2026 | +0.4% |
| Dec 2025 | +0.5% |
| Sep 2025 | +0.2% |
| Jun 2025 | -2.7% |
| Mar 2025 | -4.2% |
| Dec 2024 | -6.4% |
| Sep 2024 | -10.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+1.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets WRBY
| FY Dec 2025 | +0.2% |
| FY Dec 2024 | -3.2% |
| FY Dec 2023 | -11.0% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | -32.6% |
| Jun 2026 | +1.1% |
| Mar 2026 | +0.2% |
| Dec 2025 | +0.2% |
| Sep 2025 | +0.1% |
| Jun 2025 | -1.4% |
| Mar 2025 | -2.2% |
| Dec 2024 | -3.2% |
| Sep 2024 | -5.4% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
no debt line filed
Return on invested capital WRBY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+0.3%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed WRBY
| FY Dec 2025 | -1.0% |
| FY Dec 2024 | -6.0% |
| FY Dec 2023 | -16.1% |
| FY Dec 2022 | -29.2% |
| FY Dec 2021 | -43.4% |
| Jun 2026 | +0.3% |
| Mar 2026 | -1.1% |
| Dec 2025 | -1.0% |
| Sep 2025 | -1.5% |
| Jun 2025 | -3.4% |
| Mar 2025 | -4.4% |
| Dec 2024 | -6.0% |
| Sep 2024 | -8.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
361.14x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing WRBY
| FY Dec 2025 | 1,089.50x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 433.43x |
| Mar 2026 | 1,053.50x |
| Dec 2025 | 1,089.50x |
| Sep 2025 | 2,758.00x |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value WRBY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+0.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield WRBY
| FY Dec 2025 | +1.8% |
| FY Dec 2024 | +1.3% |
| FY Dec 2023 | +0.5% |
| FY Dec 2022 | -3.3% |
| FY Dec 2021 | -1.5% |
| Jun 2026 | +0.6% |
| Mar 2026 | +1.6% |
| Dec 2025 | +1.8% |
| Sep 2025 | +1.2% |
| Jun 2025 | +2.1% |
| Mar 2025 | +2.1% |
| Dec 2024 | +1.3% |
| Sep 2024 | +1.8% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
PEG, trailing WRBY
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $871.9M | $771.3M | $669.8M | $598.1M |
| Gross profit | $470.6M | $426.8M | $365.2M | $341.1M |
| Operating income | -$5.3M | -$30.1M | -$72.0M | -$111.2M |
| Net income | $1.6M | -$20.4M | -$63.2M | -$110.4M |
| EPS (diluted) | 0.01 | -0.17 | -0.54 | -0.96 |
| Operating cash flow | $110.8M | $98.7M | $61.0M | $10.4M |
| Cash | $286.4M | $254.2M | $216.9M | $208.6M |
| Buybacks | n/a | n/a | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-27
WRBY Stock Sonar score 5/7 axes
Find similar shapesCompareWRBY ranks highest on institutional and government (82nd percentile) and profitability (70th), and lowest on insider conviction (4th), among Medical Devices peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
WRBY filings, in plain words
Are Warby Parker insiders buying or selling WRBY?
In the 180 days to 2026-10-27, Warby Parker insiders were net sellers, a net $23.5M across purchases and sales reported on Form 4, by 6 sellers.
Are there planned insider sales of WRBY?
Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-27, covering $3.2M of stock; the latest, by NEIL BLUMENTHAL, was filed 2026-10-01.
Read the full summary
In the 180 days to 2026-10-27, Warby Parker insiders were net sellers of WRBY, a net $23.5M across purchases and sales reported on Form 4 by 6 sellers. 14% of the 14 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-27, covering $3.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
